» Articles » PMID: 31712099

Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers

Overview
Journal Am J Med
Specialty General Medicine
Date 2019 Nov 13
PMID 31712099
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Migraine headaches are among the most common and potentially debilitating disorders encountered by primary healthcare providers. In the treatment of acute migraine and the prevention of recurrent attacks, there are prescription drugs of proven benefit. However, for those without health insurance or high co-pays, these drugs may be neither available nor affordable and, for all patients, they may be either poorly tolerated or contraindicated. The totality of evidence, which includes data from randomized trials, suggests that high-dose aspirin, in doses from 900 to 1300 mg, taken at the onset of symptoms, is an effective and safe treatment option for acute migraine headaches. In addition, the totality of evidence, including some, but not all, randomized trials, suggests the possibility that daily aspirin, in doses from 81 to 325 mg, may be an effective and safe treatment option for the prevention of recurrent migraine headaches. The relatively favorable side effect profile of aspirin and extremely low costs compared with other prescription drug therapies may provide additional options for primary healthcare providers in the treatment of both acute and recurrent migraine headaches.

Citing Articles

Short-term efficacy of right-to-left shunt closure in patients with vestibular migraine.

Lang Y, Zhang S, Xie P, Wang Y, Wang C, Wang W Front Neurol. 2024; 15:1500918.

PMID: 39734627 PMC: 11672335. DOI: 10.3389/fneur.2024.1500918.


Analysis of Acupoint Selection and Combinations in Acupuncture Treatment of Migraine: A Protocol for Data Mining.

He Y, Wu Y, Li X J Pain Res. 2024; 17:4149-4157.

PMID: 39679427 PMC: 11645895. DOI: 10.2147/JPR.S489296.


Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium.

Gawde P, Shah H, Patel H, Bharathi K, Patel N, Sethi Y Cureus. 2023; 15(2):e34553.

PMID: 36879707 PMC: 9985459. DOI: 10.7759/cureus.34553.


Clinical characteristics and management of headache in patients with myeloproliferative neoplasms.

Shimoyama T, Yamaguchi H, Kimura K, Suzuki F, Hayashi T, Wakita S Front Neurol. 2022; 13:1051093.

PMID: 36561301 PMC: 9764390. DOI: 10.3389/fneur.2022.1051093.


Migraine in Patients Undergoing PFO Closure: Characterization of a Platelet-Associated Pathophysiological Mechanism: The LEARNER Study.

Trabattoni D, Brambilla M, Canzano P, Becchetti A, Teruzzi G, Porro B JACC Basic Transl Sci. 2022; 7(6):525-540.

PMID: 35818509 PMC: 9270571. DOI: 10.1016/j.jacbts.2022.02.002.